Business
Isodiol International Inc. Updates Frequently Asked Questions (FAQs) in Response to Recent Shareholder Inquiries
Isodiol International Inc. Updates Frequently Asked Questions (FAQs) in Response to Recent Shareholder Inquiries.
About this update from Isodiol International Inc
[{"type":"text","content":"\nVANCOUVER, British Columbia, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE: ISOL) (OTCQB:ISOLF) (FSE: LB6B.F) (the “Company” or “Isodiol”) today announced the release of updates to its Frequently Asked Questions (FAQs) and related responses, which are available online via the Company’s website at https://isodiol.com/frequently-asked-questions/. \n “We are aware there is a campaign by certain individuals to defame and discredit Isodiol through certain social media and investor forums,” said Isodiol’s CEO, Marcos Agramont. “It is not our general practice to respond to negative editorial remarks, as we typically prefer to communicate with our shareholders through news releases.  However, recent inquiries to our investor relations department have persuaded us to provide additional resources of information concerning recurring questions of a similar nature.  We hope our stakeholders will view these FAQs in the spirit of transparency as they are intended.” The Company will endeavor to update these FAQs from time to time as circumstances permit. Follow Our Corporate Updates On Facebook at www.facebook.com/IsodiolInternationalInc/, on Twitter @Isodiolintlinc, and on Instagram @isodiol. About Isodiol International Inc. Isodiol International Inc. is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based Consumer Packaged Goods (CPG) and solutions. Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. The Company received approval for its CBD as an Active Pharmaceutical Ingredient (API) for use in Finished Pharmaceutical Products (FPPs), as was announced on April 26, 2018.  Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe through the proliferation of its various brands, including the recently acquired CBD Naturals® portfolio of brands and proprietary technologies. ON BEHALF OF THE BOARD Marcos Agramont, CEO & Director INV...